Combinations of plasma and digital cognitive markers show promise for scalable diagnosis and prognosis of ADRD. 1 key finding →
Participants: 49 Evidence: low
Full summary, score breakdown and related studies → Original source
34,580 published Alzheimer's and dementia studies, each summarized in plain English, scored out of 100 and linked to the original paper.
Combinations of plasma and digital cognitive markers show promise for scalable diagnosis and prognosis of ADRD. 1 key finding →
Participants: 49 Evidence: low
Full summary, score breakdown and related studies → Original source
GFAP, NfL, and p-tau181 are valuable predictors of cognition and function across common neurodegenerative diseases, and may be useful in specialized clinics and clinical trials. 2 key findings →
Participants: 480 Evidence: moderate
Full summary, score breakdown and related studies → Original source
LMW-specific p-tau assays could be more useful in the diagnostic workup of AD, especially in population-based communities where conditions causing peripheral neuropathy are frequent. 5 key findings →
Participants: 668 Evidence: low
Full summary, score breakdown and related studies → Original source
These relatively non-invasive tests may be beneficial for clinical screening after replication in other populations and validation through neuroimaging or cerebrospinal fluid analysis. 2 key findings →
Participants: 787 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Plasma p-tau217 is an accurate indicator of amyloid pathology in a heterogeneous cohort and is superior to other plasma biomarkers assessed. 2 key findings →
Participants: 598 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Although genetic Aβ variants cause early-onset Alzheimer's disease, literature reports on Aβ properties are heterogeneous, obscuring molecular mechanisms, as illustrated by recent failures of Aβ-level targeting trials. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
ACAD's traction indicates the feasibility of recruiting Asians for clinical research to enhance understanding of AD risk factors. 1 key finding →
Participants: 606 Evidence: moderate
Full summary, score breakdown and related studies → Original source
A two-step workflow based on p-tau217 and confirmatory amyloid PET could accurately classify AD patients showing low/intermediate tau burden. 1 key finding →
Participants: 361 Evidence: low
Full summary, score breakdown and related studies → Original source
Wave-CAIPI offers fast high-resolution FLAIR acquisitions with comparable performance for ARIA-E monitoring. 1 key finding →
Participants: 20 Evidence: low
Full summary, score breakdown and related studies → Original source
Plasma β-synuclein demonstrated discriminative properties for Aβ PET positive and negative subjects. 3 key findings →
Design: longitudinal study Participants: 51 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
This study is the first to document concurrent prevalence of primary dementia subtypes among this US population. 1 key finding →
Participants: 21 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
During follow-up, 60 individuals developed dementia, of which 49 had Alzheimer's disease (AD). 4 key findings →
Participants: 1,322 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The MIND diet is associated with both higher cognition and slower rates of cognitive decline, after controlling for neuropathology, indicating the MIND diet may be important to cognitive resilience. 3 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source
Closer Mediterranean diet adherence was associated with lower risk of cognitive impairment but not slower decline in cognitive function. 5 key findings →
Participants: 7,756 Evidence: high
Full summary, score breakdown and related studies → Original source
A brain transcriptomic profile for healthy diets revealed novel genes potentially associated with cognitive health. 5 key findings →
Participants: 1,204 Evidence: low
Full summary, score breakdown and related studies → Original source
These findings highlight the diagnostic and longitudinal monitoring potential of GFAP and p-tau for preclinical AD. 5 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source
N-p-tau217 and N-p-tau181 could improve diagnostic accuracy in prodromal-AD and clinical trial recruitment as both identify Aβ pathophysiology and differentiate early MCI-AD better than Mid-p-tau181. 2 key findings →
Participants: 503 Evidence: low
Full summary, score breakdown and related studies → Original source
Plasma P-tau181/Aβ42 ratio may be a noninvasive means of identifying AD with elevated brain amyloid in populations with concomitant CeVD. 3 key findings →
Participants: 43 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Plasma p-tau is a stronger indicator of a temporally linked response to elevated brain Aβ than of tau pathology. 4 key findings →
Participants: 1,408 Evidence: low
Full summary, score breakdown and related studies → Original source
Both atrophy (AUC = 0.87, 95% confidence interval [95% CI: 0.79 to 0.94]) and NfL (AUC = 0.89, 95% CI: 0.81 to 0.96) showed significant predictive ability, which improved when combined (AUC = 0.93, 95% CI: 0.87 to 0.99). 5 key findings →
Participants: 55 Evidence: low
Full summary, score breakdown and related studies → Original source
Among all participants, high p-tau217 alone [p-tau217(+)NfL(-)GFAP(-)] was associated with a steeper decline in episodic/semantic memory and processing speed compared to the all-low group (p ≤ 0.02). 5 key findings →
Participants: 523 Evidence: low
Full summary, score breakdown and related studies → Original source
In the CU, using combined plasma Aβ42/40 and p-tau217 cut-offs for eligibility yielded the lowest sample size estimates for a comprehensive multidomain cognitive composite score, whereas sample sizes were higher for all other inclusion criteria based on single biomarkers. 5 key findings →
Participants: 225 Evidence: moderate
Full summary, score breakdown and related studies → Original source
The study included 381 MCSA and 584 BioFINDER-2 participants. 5 key findings →
Participants: 381 Evidence: moderate
Full summary, score breakdown and related studies → Original source
After multivariable adjustment, longer sleep duration was associated with lower Aβ42/40, poor sleep quality with higher NfL, daytime sleepiness with both lower Aβ42/40 and higher NfL, and insomnia symptoms with higher SPARE-AD. 3 key findings →
Participants: 1,325 Evidence: low
Full summary, score breakdown and related studies → Original source
Physical activity moderated the association between MTA and plasma Aβ42/40 level and increased dementia risk. 5 key findings →
Participants: 1,044 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 34,580 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 34,580 records, built mostly from automated pulls of Europe PMC (68.8% of the library) and OpenAlex (14.7%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,050 records (3% of the library) are not peer-reviewed — 966 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →
Newest studies, as a dated timeline → Atom feed Where this research is being discussed: events
Last updated